Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur J Gastroenterol Hepatol ; 28(12): 1468-1472, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27541710

RESUMEN

AIM: The aim of this study was to determine demographic and clinical features in children diagnosed with gallstones, risk factors for gallstone formation, the effectiveness of ursodeoxycholic acid therapy, and the course of the disease. MATERIALS AND METHODS: Patients aged 0-18 years were followed up for at least 6 months after the diagnosis of gallstones with ultrasonography and were evaluated retrospectively. Patients were evaluated with respect to age, sex, presenting symptoms, BMI, facilitating factors, accompanying diseases, family history of gallstones, history of ceftriaxone use, laboratory tests, ultrasonography findings and follow-up, and therapeutic approaches and results. RESULTS: The study was completed with 70 patients. Thirty-nine (55.7%) patients were females. The mean age of the patients was 9.3±5.29 (0.3-18) years. The mean age among females was statistically significantly higher than that among males (P=0.007).No risk factor for stone formation was encountered in 50% of cases, whereas a family history of gallstones was present in 17.1%. Use of ceftriaxone was present in 8.6% of cases, total parenteral nutrition in 10%, obesity in 5.7%, hereditary spherocytosis in 4.3%, and Down's syndrome in 4.3%. The probability of dissolution of stones was 3.6 times higher in patients with stone sizes up to 5 mm [odds ratio (OR): 3.65, P=0.020], 3.9 times higher in those aged younger than 2 years (OR: 3.92, P=0.021), and 13.9 times higher in those with a single stone (OR: 13.97, P=0.003). CONCLUSION: Our findings show that unknown causes are still prevalent in stone formation and that ursodeoxycholic acid exerts no effect on stone dissolution; however, diagnosis at younger than 2 years of age, a single stone, and small size of stone are factors affecting dissolution.


Asunto(s)
Antibacterianos/uso terapéutico , Ceftriaxona/uso terapéutico , Cálculos Biliares/epidemiología , Obesidad/epidemiología , Nutrición Parenteral Total/estadística & datos numéricos , Adolescente , Distribución por Edad , Niño , Preescolar , Colagogos y Coleréticos/uso terapéutico , Colecistectomía , Familia , Femenino , Estudios de Seguimiento , Cálculos Biliares/etiología , Cálculos Biliares/terapia , Humanos , Lactante , Masculino , Anamnesis , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Distribución por Sexo , Resultado del Tratamiento , Ácido Ursodesoxicólico/uso terapéutico
2.
Int J Infect Dis ; 19: 13-9, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24211227

RESUMEN

BACKGROUND: The aim of this study was to delineate mortality indicators in pneumococcal meningitis with special emphasis on therapeutic implications. METHODS: This retrospective, multicenter cohort study involved a 15-year period (1998-2012). Culture-positive cases (n=306) were included solely from 38 centers. RESULTS: Fifty-eight patients received ceftriaxone plus vancomycin empirically. The rest were given a third-generation cephalosporin alone. Overall, 246 (79.1%) isolates were found to be penicillin-susceptible, 38 (12.2%) strains were penicillin-resistant, and 22 (7.1%) were oxacillin-resistant (without further minimum inhibitory concentration testing for penicillin). Being a critical case (odds ratio (OR) 7.089, 95% confidence interval (CI) 3.230-15.557) and age over 50 years (OR 3.908, 95% CI 1.820-8.390) were independent predictors of mortality, while infection with a penicillin-susceptible isolate (OR 0.441, 95% CI 0.195-0.996) was found to be protective. Empirical vancomycin use did not provide significant benefit (OR 2.159, 95% CI 0.949-4.912). CONCLUSIONS: Ceftriaxone alone is not adequate in the management of pneumococcal meningitis due to penicillin-resistant pneumococci, which is a major concern worldwide. Although vancomycin showed a trend towards improving the prognosis of pneumococcal meningitis, significant correlation in statistical terms could not be established in this study. Thus, further studies are needed for the optimization of pneumococcal meningitis treatment.


Asunto(s)
Antibacterianos/uso terapéutico , Ceftriaxona/uso terapéutico , Cefalosporinas/uso terapéutico , Meningitis Neumocócica/tratamiento farmacológico , Resistencia a las Penicilinas , Vancomicina/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Quimioterapia Combinada , Femenino , Humanos , Masculino , Meningitis Neumocócica/mortalidad , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Penicilinas/farmacología , Estudios Retrospectivos , Resultado del Tratamiento , Turquía/epidemiología , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...